Outpatient Cervical Preparation to Reduce Induction Duration in NTSV Women (OCPRID)

March 31, 2021 updated by: University of California, Davis

Outpatient Cervical Preparation to Reduce Induction Duration in Nulliparous Term Singleton Vertex Women: A Randomized Controlled Trial

This study is to compare 2 groups in nulliparous women undergoing cervical ripening for induction of labor. The study hypothesis is that outpatient cervical preparation with a foley catheter can reduce the induction of labor (IOL) time interval from admission to delivery by 50%. A 30 ml transcervical foley catheter is a safe mode of cervical preparation in the outpatient setting, as concluded in Diederen et al, Sciscinoe et al, and Kelly et al. Findings from studies on nulliparous, term, singleton vertex (NTSV) showed patients can be applied to a wide variety of maternity unit sizes as discussed by Main et al. No previous study has evaluated the effectiveness of outpatient cervical preparation in the NTSV population by PUBMED search. Further, no previous study has assessed patient satisfaction cervical preparation in the outpatient setting and no previous study has evaluated whether outpatient cervical preparation has an impact on the length of stay and cost of hospitalization. This study will explore these important questions with the goal of improving current practices in labor induction to be more patient-centered, pragmatic, and cost-effective.

Study Overview

Detailed Description

Each participant who is offered an induction of labor from the University of California (UC) Davis Obstetrics and Gynecology clinics will be screened for inclusion criteria. If the participant meets inclusion criteria the participant will be given general information about the study and asked if they would like to participate. If so, research coordinators will meet the participant either during the current clinic visit or a subsequent clinic visit to consent and enroll the participant in the study. During this meeting, the participant will be randomly assigned to Group 1 or Group 2 by using randomization.com and subject number.

Group 1: Treatment

The participant will be given an appointment for fetal monitoring and transcervical foley catheter placement at the Antenatal Testing Unit of the UC Davis Ambulatory Care Center. This may be a same-day appointment. Once the participant presents for her appointment, participant will undergo a routine cervical examination, and routine ultrasound examination for fetal presentation and deep vertical pocket. The participant will also have vitals taken and undergo a brief interview with a provider to rule out rupture of membranes, significant vaginal bleeding, and other perinatal concerns. In order to undergo outpatient cervical preparation, the participant must meet the following criteria: Bishop's score <6 on cervical exam; Normal deep vertical pocket; Cephalic presentation; Negative standard interview to screen for vaginal bleeding, rupture of membranes, labor, and pre-eclampsia; and Blood pressure below 160 bpm systolic and 110 bpm diastolic.

If the participant meets the above criteria for outpatient cervical preparation, a 30 mL transcervical foley catheter will be placed. If the participant does not meet criteria, participant will be sent to Labor and Delivery for possible admission. The participant may elect to receive pain medication intramuscularly for pain management before or after foley catheter placement. After catheter placement the participant will undergo a nonstress test (NST), and if there is no evidence of tachysystole or non-reassuring fetal well-being, participant will be discharged home with a prescription for tylenol. Upon discharge home, the participant will receive instructions on keeping catheter on gentle traction and walking. The participant will be instructed to return once the foley is expelled, or after 24 hours with the foley in place. The participant will also leave with return precautions including rupture of membranes, vaginal bleeding, decreased fetal movement, labor, severe pain, and signs or symptoms of preeclampsia. As a safety measure, the participant will be counseled to call an 24 hour advice nurse line if participant experiences any of the following: Severe pain or discomfort (greater than 8 out of a 10 point scale); Vaginal bleeding; Loss of fluid; Contractions more than 5 minutes apart; Decreased fetal movement; Fevers or chills; Severe headache; Abdominal pain under right rib area; and Spots in vision or blurry vision.

The remaining procedures in this group will follow the standard Labor and Delivery hospital procedures at UC Davis

Group 2: Control The participant will be admitted to Labor and Delivery. The remaining procedures in this group will follow standard Labor and Delivery hospital procedures at UC Davis

The duration anticipated to enroll all study subjects is 10-14 months after Institutional Review Board approval. Approximately 30-40 participant are admitted each month to UC Davis Labor and Delivery. On average, half of these participants are nulliparous. If approximately 5- 10 participants are recruited to each group each month, it will take 10-14 months to reach the goal number of subjects. The duration of an individual subject's participation in the study will be from time of foley catheter insertion (Group 1) or hospital admission time (Group 2) to the time of hospital discharge. Electronic medical records will be accessed during and after this time period only pertaining to the participant's labor including intrapartum and postpartum complications. In addition, participants will be asked survey questions at the time of study enrollment and on postpartum day 1. The estimated date for the investigators to complete this study is two months after enrollment has ended.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Sacramento, California, United States, 95817
        • University of California Davis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Nulliparous women >18 years of age
  • Singleton live pregnancy
  • Vertex presentation
  • Scheduled induction of labor between 37 and 42 weeks gestation
  • Bishop score <6

Exclusion Criteria:

  • Regular painful contractions (> every 5 minutes)
  • Oligohydramnios or anhydramnios
  • Breech presentation
  • Rupture of membranes
  • Fetal heart tracing with minimal variability or significant decelerations with >50% contractions
  • Prior vaginal or cesarean delivery
  • Contraindication to vaginal delivery (including placenta previa, morbidly adherent placenta, active genital herpes)
  • Known or suspected placental abruption
  • Major fetal anomaly
  • Poorly controlled hypertension (using 2 or more medications; newly diagnosed preeclampsia; preeclampsia with severe features; superimposed preeclampsia)
  • Poorly controlled diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Treatment
Patients for IOL with intracervical balloon placed in the outpatient clinic and sent home
Patients for IOL are sent home after placement of intracervical balloon
NO_INTERVENTION: Control
Patients for IOL admitted to Labor and Delivery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of time from admission for IOL to delivery
Time Frame: 24 hours
The time difference from admission to delivery of the infant
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total time of oxytocin use
Time Frame: 24 hours
time from start to discontinuation prior to delivery
24 hours
Cesarean delivery
Time Frame: 12 months
proportion of cesarean section
12 months
Blood transfusion
Time Frame: 12 months
binary - yes or no
12 months
Neonatal intensive care unit (NICU) admission
Time Frame: 12 months
Binary - yes or no
12 months
Apgar score at 5 minutes less than 7
Time Frame: 5 minutes after birth
Binary - yes or no
5 minutes after birth

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cost of hospitalization
Time Frame: 12 months
charges incurred by the patient for all procedures performed including occupancy fees
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Herman L Hedriana, MD, University of California Davis Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

December 1, 2020

Primary Completion (ANTICIPATED)

June 1, 2021

Study Completion (ANTICIPATED)

June 1, 2022

Study Registration Dates

First Submitted

April 18, 2019

First Submitted That Met QC Criteria

April 29, 2019

First Posted (ACTUAL)

May 2, 2019

Study Record Updates

Last Update Posted (ACTUAL)

April 5, 2021

Last Update Submitted That Met QC Criteria

March 31, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 1233410

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Patient Satisfaction

Clinical Trials on Treatment

Subscribe